JPRN-jRCT2080220258未知2 期
An Open-Label, Randomized, Parallel Group, Multicentre Study to Compare Oestradiol Suppression Between ZOLADEX 10.8 Mg Depot Given 3 Monthly and ZOLADEX 3.6 Mg Depot Given Monthly in Pre-Menopausal Patients With ER Positive Early Breast Cancer
适应症
试验速览
- 阶段
- 2 期
- 发起方
- AstraZeneca
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- Female
入选标准
- •Ages Eligible for Study: 20 Years and above, Genders Eligible for Study: Female
- •Inclusion Criteria:
- •Pre-menopausal women aged 20 years or over with histological/cytologically-confirmed ER +ve breast cancer who have undergone radical surgery and WHO performance status 0,1 or 2.
排除标准
- •Evidence of metastatic disease, previous bilateral oophorectomy or radiotherapy to the ovaries, previous chemotherapy, breast surgery completed over 12 weeks before starting trial treatment, previous neo-adjuvant/adjuvant hormonal breast cancer therapy
研究者
相似试验
未知
2 期
An Open-Label, Randomised, Parallel Group, Multicentre Study to Compare ZOLADEX 10.8 mg Given Every 12 Weeks With ZOLADEX 3.6 mg Given Every 4 Weeks in Pre-Menopausal Women With Oestrogen Receptor Positive Advanced Breast CancerAdvanced Breast CancerJPRN-jRCT2080220406AstraZeneca
招募中
3 期
A large study in kids from birth to 18 years of age that have a documented clot in their lung or limbs, to test a new drug (edoxaban) used for treatment or the prevention of recurrent clots in your body.CTRI/2019/04/018361Daiichi Sankyo
进行中（未招募）
不适用
An Open Label, Randomised, Parallel Group, Multicentre Study toCompare ZOLADEX™ 10.8 mg Given Every 12 Weeks with ZOLADEX3.6 mg Given Every 4 Weeks in Pre-menopausal Women with OestrogenReceptor Positive Advanced Breast CancerEUCTR2005-004001-29-CZAstraZeneca AB260
未知
3 期
An Open Label, Randomised, Parallel Group, Multicentre Study to Compare ZOLADEX 10.8 mg Given Every 12 Weeks With ZOLADEX 3.6 mg Given Every 4 Weeks in Pre-menopausal Women With Oestrogen Receptor Positive Advanced Breast CancerBreast CancerJPRN-jRCT2080221070AstraZeneca
进行中（未招募）
1 期
A Randomized, Open-label, Parallel Group, Multicenter Pilot Study Evaluating the Efficacy and Safety of Alternative Dosing of Ribavirin vs. Standard of Care Dosing in Combination with Peginterferon alpha-2a in Interferon Naïve Patients with Chronic Hepatitis C Genotype 1 Infection - RibaCChronic hepatitis C infectionMedDRA version: 12.1Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2010-018332-41-DKDept. of Infectious diseases / virology University of Gothenburg105